HER2/Neu Over-expressing Locally Advanced Breast Cancer
1 clinical trials · Condition
◉ Watch HER2/Neu Over-expressing Locally Advanced Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (NCT01007942) | Novartis Pharmaceuticals | 2009-10-01 |
Track HER2/Neu Over-expressing Locally Advanced Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.